布鲁顿酪氨酸激酶作为治疗白血病和淋巴瘤以及炎症性疾病和自身免疫的分子靶点。
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
机构信息
University of Southern California Keck School of Medicine, Children's Center for Cancer and Blood Diseases, Division of Hematology-Oncology, Department of Pediatrics, Los Angeles, CA 90027-0367, USA.
出版信息
Expert Opin Ther Pat. 2010 Nov;20(11):1457-70. doi: 10.1517/13543776.2010.517750. Epub 2010 Sep 10.
IMPORTANCE OF THE FIELD
Bruton's tyrosine kinase (BTK) has emerged as a new anti-apoptotic molecular target for the treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that BTK inhibitors may be useful in the treatment of leukemias and lymphomas. BTK inhibitors may also be helpful in prevention and treatment of thromboembolic complications as well as inflammatory disorders.
AREAS COVERED IN THIS REVIEW
We provide a comprehensive review of the target diseases for which the use of BTK inhibitors may be helpful as well as the activity profiles of BTK inhibitors.
WHAT THE READER WILL GAIN
We review the currently available translational research, biomarker as well as patent literature regarding BTK molecular target and BTK inhibitors.
TAKE HOME MESSAGE
BTK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias/lymphomas, inflammatory disorders and autoimmunity.
重要性领域
布鲁顿酪氨酸激酶（BTK）已成为治疗 B 细胞白血病和淋巴瘤的新型抗凋亡分子靶点。临床前和早期临床结果表明，BTK 抑制剂可能对白血病和淋巴瘤的治疗有用。BTK 抑制剂也可能有助于预防和治疗血栓栓塞并发症以及炎症性疾病。
本综述涵盖的领域
我们提供了对可能有助于 BTK 抑制剂使用的目标疾病以及 BTK 抑制剂的活性谱的全面综述。
读者将获得什么
我们回顾了关于 BTK 分子靶点和 BTK 抑制剂的转化研究、生物标志物和专利文献。
重要信息
BTK 抑制剂可能为针对 B 细胞白血病/淋巴瘤、炎症性疾病和自身免疫的治疗创新提供基础。
Zotero 插件